UBR7: A Potential Drug Target and Biomarker for Ubiquitin-Protein Ligase Enzymes

Target Name: UBR7

NCBI ID: G55148

UBR7

UBR7: A Potential Drug Target and Biomarker for Ubiquitin-Protein Ligase Enzymes

Ubiquitin (U) proteins are a family of highly conserved, small modulators of various cellular processes, including DNA damage repair, cell signaling, and inflammation. They play a crucial role in ensuring the stability and integrity of damaged cellular structures and have been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Ubiquitin-protein ligase enzymes, such as UBR7, are involved in the removal of damaged or dysfunctional proteins, thereby maintaining protein homeostasis and contributing to cellular quality control.

UBR7: A Putative Drug Target

The discovery of UBR7 as a potential drug target comes from a series of studies that have identified its involvement in various cellular processes, including the regulation of cell cycle progression, apoptosis, and inflammation. UBR7 has been shown to play a critical role in the ubiquitin-protein ligase pathway, a critical pathway for protein degradation and homeostasis.

Drugs that target UBR7 have the potential to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, UBR7 has been shown to promote the growth and survival of cancer cells, making it an attractive target for anti-cancer drugs. Additionally, UBR7 has been linked to the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, making it a potential target for these conditions.

UBR7: A Biomarker

The identification of UBR7 as a potential drug target also has the potential to serve as a biomarker for certain diseases. For example, UBR7 has been shown to be overexpressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Overexpression of UBR7 has been linked to the development and progression of these diseases, making it a potential indicator for disease progression and treatment response.

Conclusion

In conclusion, UBR7 is a promising drug target and biomarker for the treatment of various diseases. The identification of its involvement in the ubiquitin-protein ligase pathway and its role in promoting the growth and survival of cancer cells make it an attractive target for anti-cancer drugs. Additionally, its link to the development and progression of neurodegenerative diseases and autoimmune disorders makes it a potential target for these conditions as well. Further research is needed to fully understand the effects of drugs that target UBR7 and to determine its utility as a biomarker for disease progression and treatment response.

Protein Name: Ubiquitin Protein Ligase E3 Component N-recognin 7

Functions: E3 ubiquitin-protein ligase which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation

The "UBR7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBR7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets